AngioInsight
AngioInsight is a medical technology company that leverages AI precision to enhance the diagnosis and management of Coronary Artery Disease (CAD) and Coronary Microvascular Disease (CMD). Their AI-powered platform, AngioAI+, provides real-time, quantitative assessment of stenosis, non-invasive measurement of blood flow, and rapid, accurate flow and anatomy data. It also offers automated workflow streamlining and detection of microvascular disease. The company aims to reduce the cost of care through improved accuracy and efficiency in cardiovascular diagnostics, addressing the significant challenges of CAD's prevalence and diagnostic inaccuracies, as well as the underdiagnosis of CMD. AngioInsight has initiated a pivotal clinical study called SMARTFLOW.
AngioInsight
AngioInsight is a medical technology company that leverages AI precision to enhance the diagnosis and management of Coronary Artery Disease (CAD) and Coronary Microvascular Disease (CMD). Their AI-powered platform, AngioAI+, provides real-time, quantitative assessment of stenosis, non-invasive measurement of blood flow, and rapid, accurate flow and anatomy data. It also offers automated workflow streamlining and detection of microvascular disease. The company aims to reduce the cost of care through improved accuracy and efficiency in cardiovascular diagnostics, addressing the significant challenges of CAD's prevalence and diagnostic inaccuracies, as well as the underdiagnosis of CMD. AngioInsight has initiated a pivotal clinical study called SMARTFLOW.
TL;DR
What they do: AI software (AngioAI+) for real-time angiographic analysis assessing stenosis, estimated FFR, and coronary microvascular disease
Clinical activity: Initiated the SMARTFLOW pivotal clinical study
Funding signal: Received an NSF grant (Jun 2022, ~$256k); later announced Series A initiation (Oct 2025)
Leadership: Appointed Scott Burger as CEO (Dec 2024)
Company Overview
Problem Domain
Cardiovascular diagnostics (Coronary Artery Disease and Coronary Microvascular Disease)
Founded
2018
Industry
Biotechnology
Tech Stack
Funding Track Record
256000
Documented NSF grant reported June 2022
Company announced initiation of a Series A round and a board appointment
Investor Signal
“Received grant funding from the National Science Foundation; announced initiation of Series A (Oct 2025)”